An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8+ T cells and antibody when expressed from modified vaccinia Ankara  by Quinan, Bárbara R. et al.
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Dengue  is  a global  public  health  concern  and  this  is aggravated  by a  lack  of  vaccines  or antiviral  therapies.
Despite  the  well-known  role  of CD8+ T cells  in the  immunopathogenesis  of  Dengue virus  (DENV),  only
recent  studies  have  highlighted  the  importance  of this  arm  of  the  immune  response  in protection  against
the  disease.  Thus,  the  majority  of  DENV  vaccine  candidates  are  designed  to achieve  protective  titers  of
neutralizing  antibodies,  with  less  regard  for  cellular  responses.  Here,  we  used  a mouse  model  to  investi-
gate  CD8+ T cell  and  humoral  responses  to a set  of  potential  DENV  vaccines  based  on  recombinant  modiﬁed
vaccinia  virus  Ankara  (rMVA).  To  enable  this  study,  we identiﬁed  two CD8+ T cell  epitopes  in  the  DENV-3
E  protein  in  C57BL/6  mice.  Using  these  we  found  that  all the  rMVA  vaccines  elicited  DENV-speciﬁc  CD8+ecombinant MVA
D8+ T cells
ytotoxic  T cells
TL
T cells  that  were  cytotoxic  in  vivo and polyfunctional  in vitro. Moreover,  vaccines  expressing  the  E protein
with  an  intact  signal  peptide  sequence  elicited  more  DENV-speciﬁc  CD8+ T cells  than  those  expressing
E  proteins  in  the  cytoplasm.  Signiﬁcantly,  it was  these  same  ER-targeted  E protein  vaccines  that  elicited
antibody  responses.  Our  results  support  the  further  development  of rMVA  vaccines  expressing  DENV  E
proteins  and add  to the tools  available  for dengue  vaccine  development.. Introduction
It is estimated that 3.6 billion people living in 124 tropical and
ubtropical countries are at risk of dengue virus (DENV) infections
1,2]. Recent evaluations suggested that more than 390 million
ndividuals are infected every year and, of these, 96 million seek
edical attention [3]. DENV belongs to the Flaviviridae family and
Abbreviations: DENV, dengue virus; MVA, modiﬁed vaccinia virus Ankara; CEF,
hicken embryo ﬁbroblasts; VACV, vaccinia virus; ICS, intracellular cytokine stain-
ng.
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has four distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-
4. Infection with one serotype provides life-long protection against
re-infection by the same serotype, but only a short-term protection
against the 3 heterologous types. The DENV E glycoprotein is a sur-
face protein and has functions that include cell receptor binding and
fusion with host cell membranes during penetration. Importantly, E
is  an immunodominant protein that harbors many antigenic deter-
minants known to elicit protective immune responses [4,5].
At  present effective vaccines against dengue are not available.
Several candidate vaccines have been developed and are currently
being evaluated in preclinical and clinical trials [6–8]. One of the
leading candidates is the Sanoﬁ Pasteur CYD vaccine, a tetravalent
live chimeric vaccine based on the 17D attenuated yellow fever
virus backbone. However, despite excellent safety and immuno-
genicity proﬁles, the efﬁcacy of this vaccine in phase 2b tests did not
meet the expected threshold [9,10]. In light of this, it is prudent to
maintain a diverse pipeline of DENV vaccine candidates. Modiﬁed
Vaccinia Ankara (MVA) has been shown to be a highly immuno-
genic recombinant vaccine vector in a number of settings, inducing
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ood antigen-speciﬁc antibody and CD8+ T cell responses [11–15].
urther, previous work has suggested that mucosal delivery of
VA-based vaccines can circumvent the problem of pre-existing
mmunity to the vector [16].
Here we present a set of MVA-vectored dengue vaccines and
stablish a model in C57BL/6 mice to explore their immunogenicity
oth for CD8+ T cells and antibodies.
. Materials and methods
.1.  Viruses and cells
Primary  chicken embryo ﬁbroblasts (CEF) were prepared as
escribed [17] and grown in Dulbecco’s modiﬁed eagle medium
DMEM) supplemented with 2 mM l-glutamine and 10% fetal
ovine serum (FBS). BHK-21 cells were grown in Minimal Essen-
ial medium (MEM)  supplemented with 2 mM l-glutamine and 10%
BS. Vaccinia virus (VACV) strain MVA, and DENV-3 were gifts from
ernard Moss (NIH, Bethesda) and John Aaskov (IHBI, Brisbane),
espectively.
.2. Recombinant viruses
Recombinant  MVAs (rMVA/E, rMVA/EM, rMVA/Sg-E and
MVA/Sg-EM) expressing a C-terminally truncated DENV-3 E
rotein were generated by homologous recombination in CEF
ells (Supplementary Fig. 1). The rMVA/E and rMVA/EM con-
ain the DNA sequence for 80% of the E glycoprotein gene
polyprotein amino acids 281–675), and the rMVA/Sg-E and
MVA/Sg-EM contain the same E sequence preceded by the
redicted N-terminal E signal peptide (polyprotein amino acids
66–675). The relevant sequences were ampliﬁed by RT-PCR
rom a DENV-3 genotype III clinical isolate (GenBank accession
 FJ850094) using the following primers: AAACCCGGGAC-
ATGGTGGTTATTTTTATACTACTAATGCTGGTCACCCCATCC,
AACCCGGGACCATGAGATGTGTGGGAGTAGGAAACAGAGATTTT-
TGGAAGG (forward primers) and TTTCTGCAGACAAAAAA-
ATCTTCCCTTAGGAGCTTCCTTTCTTATACCAGTTG (reverse
rimer). Viruses rMVA/EM and rMVA/Sg-EM also have an
nternally located Kozak sequence eliminated through use of
he QuikChange Site-Directed Mutagenesis Kit (Stratagene).
rimers CGGAGGGTGTGTGACTTCGATGGCTAAGAACAAGC and
CTTGTTCTTAGCCATCGAAGTCACACACCCTCCG were used for
utagenesis. The PCR products were inserted into the SmaI and
stI sites of pLW44 plasmid (provided by Bernard Moss) [18] to
reate transfer plasmids. Plasmid pLW44 contains homologous
equences ﬂanking the Deletion III region of MVA  genome and
reen ﬂuorescent protein (GFP) under the p11 late promoter.
xogenous gene expression is controlled by the strong mH5  pro-
oter, a late/early promoter. Transfer plasmids were sequenced
nd used to generate the recombinant MVAs. To this end, plasmids
ere transfected into CEF cells previously infected with MVA
nd, after 2 days, the recombinant MVAs were picked. Selection
f recombinants was ensured through six successive rounds of
laque puriﬁcation using the visual aid of GFP expression. MVAs
ere grown in BHK-21 and puriﬁed by centrifugation through a
6% sucrose cushion before titration in BHK-21 cells. Expression
f the various E protein variants in infected cells was tested by
estern-blotting (Supplementary Fig. 1C). Cells were infected
t MOI  of 1 and after 24 h lysates in electrophoresis loading
uffer (240 mM Tris–HCl pH 6.8; 40% glycerol; 0.8% SDS; 0.02%
romophenol blue; -mercaptoethanol 200 mM)  were obtained.
roteins were electrophoresed and blotted onto PVDF membranes
GE Healthcare, HybondTM-P). Proteins were probed using mouse
nti-DENV 1 + 2 + 3 + 4 (ab9202, Abcam®) and rabbit anti-mouse2 (2014) 2972–2979 2973
IgG  HRP (A9044, SIGMA) as secondary antibody. Blots were
revealed using ECLTM Plus Western-blotting Detection System (GE
Healthcare) and Amersham Hyperﬁlm ECL (GE Healthcare).
2.3.  Synthetic peptides
Putative  CD8+ T cell epitopes for DENV-3 E protein binding to H-
2d and H-2b MHC  I molecules were predicted as described in Section
3. Control peptides used were: MVA  A3270, KSYNYMLL [19] and
herpes simplex virus gB452, YQPLLSNTL [20]. Synthetic peptides
were purchased from Mimotopes (Clayton, Australia), stocks at
10 mg/ml  in dimethylsulfoxide (DMSO) were diluted to the desired
concentration in serum-free DMEM.
2.4. Mice and infections
Female  BALB/c, C57BL/6, and C57BL/6.SJL mice, older than 8
weeks, were obtained from the ANU Bioscience Resource Facil-
ity. For cellular analysis, mice were immunized intraperitoneally
(i.p.) with 1 × 106 PFU of recombinant MVA  in 200 l of PBS. Alter-
natively mice were infected i.p. with 200 l of DENV-3 (D94.283)
[21]. To analyze humoral responses, mice were immunized intra-
dermally (i.d.) [22] using two doses, 28 days apart, with each
containing 107 PFU of MVA  or 10 g recombinant E protein plus
adjuvant (saponin, Sigma) in 10 l of PBS. All animal procedures
were conducted in compliance with ethical requirements and
approved by the Australian National University (ANU) Animal
Ethics and Experimentation Committee.
2.5. Peptide stimulation and intracellular cytokine staining (ICS)
of  IFN- and TNF-˛
Mice  were euthanized 7 or 42 days after immunization and
spleens were taken for analysis of CD8+ T cell responses by ICS
[23]. Brieﬂy, 1 × 106 splenocytes were incubated with peptides
(10−5 to 10−12 M ﬁnal) at 37 ◦C with 5% CO2. After 1 h, 1 g of
Brefeldin A (Sigma) was added to each well and plates were incu-
bated for another 3 h. Cells were then stained for surface CD8
(clone 53-6.7, BioLegend) before ﬁxing and stained for intracellu-
lar cytokines (anti-IFN--APC, clone XMG1.2; anti-TNF--PE-Cy7
clone MP6-XT22) in the presence of 0.5% saponin (Sigma). Results
were acquired using a FACS LSR II (BD Biosciences) and analyzed
with Flowjo software (Tree Star Inc.). Backgrounds were deter-
mined by using control wells with no peptides for each mouse and
were subtracted from the values of test samples.
2.6. Staining of CD107a/b
Splenocytes  were incubated with peptides as above but with the
addition of Golgi-Stop (BD Biosciences) and anti-CD107a/b-FITC.
After this incubation, cells were stained for surface CD8  and intra-
cellular IFN-. Acquisition, analysis and subtraction of background
were as described above.
2.7.  In vivo cytotoxicity assay
Splenocytes from C57BL/6.SJL (CD45.1+) mice were pulsed
10−6 M peptide for use as targets. Three treatments of these
were done with different peptides and amounts of CFSE label:
(1) gB452, as an irrelevant peptide and 5 M CFSE; (2) D3E284–292
and 0.5 M CFSE; (3) D3E408–415 and no CFSE. These cells were
mixed in equal proportion and a total of 5 × 106 injected by
intravenous (i.v.) injection into C57BL/6 mice 7 days after immu-
nization. Mice were euthanized after 22 h and the recovery of
each of the cell populations described above determined by ﬂow
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Table 1
DENV-3 E epitopes predicted.
Namea Sequence MHC  % IFN-+ (of CD8+)b
D3E284–292 VGVGNRDFV H-2Db 0.27
D3E313–321 TMAKNKPTL H-2Db –
D3E365–375 EQDQNYVCKHT H-2Db –
D3E369–377 NYVCKHTYV H-2Db/H-2Kd –
D3E408–419 KVVQYENLKYTV H-2Db/H-2Kb 1.17
D3E411–420 QYENLKYTVI H-2Kd/H-2Db –
D3E416–423 KYTVIITV H-2Kd/H-2Db –
D3E429–439 HQVGNETQGVT H-2Db –
D3E443–453 TPQASTTEAIL H-2Ld –
D3E463–471 CSPRTGLDF H-2Dd/H-2Ld –
D3E489–496 QWFFDLPL H-2Db/H-2Kd –
D3E540–548 TALTGATEI H-2Db/H-2Kd –
D3E576–586 SYAMCTNTFVL H-2Kd –
a Numbers in subscripts represent the amino acid positions in DENV-3 polypro-
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ytometry. The following formula was used to determine spe-
iﬁc lysis. Ratio = (percentage CFSEhigh/percentage CFSElow) for
3E284–292 or ratio = (percentage CFSEhigh/percentage CFSEneg) for
3E408–415. Percent speciﬁc lysis = [1− (ratio naïve mouse/ratio
nfected mouse) × 100].
.8. ELISA
Serum was taken 14 days after the ﬁnal immunization and
ested in duplicate for anti-E IgG antibodies. Nunc Maxisorp®
lates were coated overnight with recombinant DENV-3 E protein
100 ng/well) in bicarbonate buffer. After blocking for 2 h with 5%
kim milk in PBS-T, diluted serum samples (1/100) were added to
he plates and incubated for 1 h at room temperature. Bound anti-
ody was detected with anti-mouse IgG-HRP (1:10,000) (#7076,
ell Signaling) and TMB  substrate at 100 l/well. Absorbance at
50 nm was then measured.
.9. Statistical analysis
Comparisons  were made using one-way ANOVA followed by
ost-analysis with Bonferroni’s multiple comparison tests (Graph-
ad Prism v5.00). Differences were considered signiﬁcant when
 ≤ 0.05.
. Results
.1. Identiﬁcation of CD8+ T cell epitopes in DENV-3 E
To  enable comparison of DENV-3 E-speciﬁc CD8+ T cell
esponses in a mouse model, we ﬁrst needed to identify H-2-
estricted epitopes in this protein. Some progress has been made in
dentifying DENV-speciﬁc CD8+ T cell epitopes, but most are in non-
tructural proteins and restricted to human MHC  alleles [24–26].
pitope identiﬁcation work in mice has focused largely on DENV-2
27,28]. For the DENV-3 E protein, several CD8+ T cell epitopes have
ig. 1. Mapping of CD8+ T cell epitopes in DENV-3 E glycoprotein. Mice were immunized
nd  7 days later, percentages of CD8+ T cells producing IFN- in response to the peptide
mmunized with rMVA/E or MVA. Nil, control with no peptide; A3270, native epitope of
ndicated concentrations. (C) As for B, but using D3E408–419 (KVVQYENLKYTV). (D) Redeﬁ
3E408–419 as shown. (E) Representative ﬂow cytometry plots for mice immunized with D
rom each immunization group producing IFN- after stimulation with the peptides show
ndividual mice for the other immunizations. Results in panel F were independently repr
f 2 (panels C and D) or 3 (panel B) experiments.tein  (GenBank accession no. FJ850094).
b Data are presented as means values from groups of 3 mice.
been predicted, but only one has been shown to be immunogenic
in DENV infection [29–31]. We  predicted H-2d- and H-2b-binding
peptides from the DENV-3 E protein sequence (FJ850094) combin-
ing results from BIMAS, IEDB and SYFPEITHI databases [32–34].
From these predictions, thirteen peptides were synthesized, in each
case we used only the longest version of any predicted binding
sequence irrespective of rank (Table 1).
Next, the peptides were used to restimulate splenocytes taken
from mice 7 days after immunization with rMVA/E (Supplemen-
tary Fig. 1) and their ability to induce IFN- production by CD8+ T
cells detected by ICS. In C57BL/6 mice, D3E284–292 (VGVGNRDFV)
and D3E408–419 (KVVQYENLKYTV), stimulated IFN- production by
CD8+ T cells (Table 1 and Fig. 1A) from mice immunized with
rMVA/E, but not MVA. These initial screens used 10−5 M peptide
so to validate and reﬁne our mapping they were tested at con-
centrations down to 10−12 M.  D3E284–292 was  able to restimulate
a half-maximal response at between 10−9 and 10−10 M and we
concluded that this sequence was likely to be optimal (Fig. 1B).
 i.p. with MVA, rMVA/E (1x106 PFU) or DENV-3 isolate D94.283 (approx. 103 PFU)
s shown were measured by ICS. (A) Representative ﬂow cytometry plots for mice
 MVA. (B) Fraction of CD8+ T cells responding to D3E284–292 (VGVGNRDFV) at the
ning the D3E408–419 peptide. Fraction of CD8+ T cells responding to the variants of
ENV-3, rMVA/Gg-E or MVA. Peptides as for panel A. (F) The percent of CD8+ T cells
n. Data are the mean and SEM from a group of four DENV-3-infected mice and are
oduced using a second isolate of DENV-3. For other panels, data are representative
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owever, half-maximal responses to D3E408–419 were >10−8 M
Fig. 1C). To map  a minimal H-2b-restricted epitope in this region,
e tested a range of peptide variations at a wide range of con-
entrations (Fig. 1D). D3E408–415 (KVVQYENL) had a half maximal
esponse at the lowest concentration among all peptides and was
hosen as the most likely minimal epitope. None of the predicted
-2d-restricted peptides were active in assays using splenocytes
rom immunized BALB/c mice and no further work was done in
his strain.
.2. D3E284–292 and D3E408–415 are recognized by CD8+ T cells
uring  DENV-3 infection
To  ensure the epitopes mapped using our vaccine were also
resented during DENV infection, D3E284–292 and D3E408–415 were
ested for their ability to stimulate IFN- production by CD8+ T cells
rom spleens of C57BL/6 mice infected 7 days earlier with a pas-
age 1 stock of DENV-3 [21]. Fig. 1E and F shows that D3E284–292
ig. 2. Immunogenicity of rMVA/DENV-3 E vaccines at acute times. C57BL/6 mice were i
 days later, splenocytes were used in ICS assays. (A and B) Percentages of CD8+ splenocy
espectively.  Data are represented as means and SEM from 3 experiments (C and D) P
timulation with D3E284-292 and D3E408-415 peptides, respectively. (E and F) Percentages of
3E284-292 and D3E408-415, respectively. Data are represented as means and SEM from 2 ex2 (2014) 2972–2979 2975
and D3E408–415 were both epitopes in the context of a DENV-3-
infection. Of these, D3E284–292 (VGVGNRDFV) has been previously
predicted [30], but not shown to be elicited by DENV infection and
the more dominant D3E408–415 is entirely novel.
3.3.  ER-targeted E protein is more immunogenic for CD8+ T cells
We then used the epitopes to investigate whether there were
differences in immunogenicity across a set of rMVA vaccines. These
vaccines, namely rMVA/E, rMVA/EM, rMVA/Sg-E and rMVA/Sg-EM,
all express 80% of DENV-3 E, but rMVA/Sg-E and rMVA/Sg-EM
address the protein to the endoplasmic reticulum (ER) via the native
signal sequence. In addition, rMVA/EM and rMVA/Sg-EM had a
potential internal Kozak sequence eliminated by mutagenesis, in
case this compromised translation of full length E protein. Western-
blotting showed that the vaccines expressed similar levels of E
protein, irrespective of the design (Supplementary Fig. 1). Groups
of mice were immunized with each of the recombinant viruses and
mmunized i.p. with 106 PFU of rMVA/Sg-E, rMVA/Sg-EM, rMVA/E or rMVA/EM and
tes that produced IFN- after stimulation with D3E284–292 and D3E408–415 peptides,
ercentages of CD8+ splenocytes with surface CD107 and intracellular IFN- after
 CD8 splenocytes that were IFN-+ and TNF-+ after stimulation with the peptides
periments. Peptide concentration was  10−7 M.  *p ≤ 0.5; **p ≤ 0.01; ***p ≤ 0.001.
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D8+ T cell responses to the DENV-3 and several native MVA  epi-
opes were measured at the peak of the acute response (7 days)
nd in memory (42 days). On day 7, there were signiﬁcantly more
D8+ T cells responding to the DENV peptides when measured by
etecting IFN- alone, IFN- and CD107, or IFN- and TNF- in mice
mmunized with MVA  vectors expressing ER-targeted E protein,
ompared to those without the signal sequence (Fig. 2). However,
here was no apparent advantage in mutating the internal Kozak
equence (Fig. 2).
For  memory responses, the trend for higher responses elicited by
accines with E proteins having signal sequences was  maintained,
ut only reached statistical signiﬁcance for D3E284–292 when mea-
ured by co-expression of intracellular IFN- and surface CD107
Fig. 3). In all experiments responses to native MVA  epitopes were
imilar across the vaccines (not shown).
ig. 3. Immunogenicity of rMVA/DENV-3 E vaccines in memory. C57BL/6 mice were imm
ays  later, splenocytes were used in ICS assays. (A and B) Percentages of CD8+ splenocyt
espectively.  (C and D) Percentages of CD8+ splenocytes with surface CD107 and intracellu
nd F) Percentages of CD8 splenocytes that were IFN-+ and TNF-+ after stimulation w
0−7 M.  Data are represented as means and SEM from 3 experiments. *p ≤ 0.5; **p ≤ 0.01;2 (2014) 2972–2979
3.4.  DENV-3 vaccines induce cytotoxic CD8+ T cells
To  ensure that our vaccines elicited DENV-3-speciﬁc cyto-
toxic CD8+ T cells, we  assessed the ability of immunized mice
to eliminate peptide loaded targets in vivo (Fig. 4) [23,35]. For
this experiment we  immunized mice with rMVA/Sg-E, rMVA/E
or used MVA  as a control and the ability of mice to kill cells
loaded with D3E284–292 and D3E408–415 was  tested 7 days later.
As expected, control MVA-immunized mice were unable to kill
either of the D3E-peptide loaded targets. Mice immunized with
each of the two  rMVA DENV-3 vaccines were able to kill tar-
gets loaded with either D3E284–292 or D3E408–415. There was
no  signiﬁcant difference in killing between the vaccines, but
the mean speciﬁc lysis for rMVA/Sg-E was higher for both epi-
topes.
unized i.p. with 106 PFU of rMVA/Sg-E, rMVA/Sg-EM, rMVA/E or rMVA/EM and 42
es that produced IFN- after stimulation with D3E284–292 and D3E408–415 peptides,
lar IFN- after stimulation with D3E284-292 and D3E408-415 peptides, respectively. (E
ith the peptides D3E284-292 and D3E408-415, respectively. Peptide concentration was
 ***p ≤ 0.001.
B.R. Quinan et al. / Vaccine 32 (2014) 2972–2979 2977
Fig. 4. Cytotoxic capacity of DENV-3 E-speciﬁc CD8+ T cells. Mice were immunized
as  in Fig. 2 and 3 and cytotoxicity measured using an in vivo assay 7 days later.
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Fig. 5. Humoral immunogenicity for rMVA/DENV-3 E vaccines. C57BL/6 mice
were  immunized i.d. through a homologous prime-boost protocol with 107 PFU ofA) Speciﬁc lysis of D3E284–292 peptide loaded cells. (B) Speciﬁc lysis of D3E408–415
eptide loaded cells. Data are represented as means and SEM from 2 experiments.
p  ≤ 0.5; **p ≤ 0.01; ***p ≤ 0.001.
.5. ER-targeted E protein generates superior antibody responses
Given  the established role for antibodies in protection against
ENV, it was important to determine if changing the cellular loca-
ion of the E protein also altered humoral responses. To test this
e immunized mice with rMVA/E, rMVA/Sg-E or controls, giving
wo doses of 107 PFU 28 days apart and then measuring antibodies
y ELISA 2 weeks after the boost. Whereas rMVA/Sg-E was  able to
nduce an easily detectable antibody response, rMVA/E elicited no
esponse distinguishable from background (Fig. 5).
.  Discussion
The quest for an effective dengue vaccine has recently reached
 milestone with a phase 2b clinical trial of the Sanoﬁ Pasteur CYD
accine in Thailand. However, the overall efﬁcacy was only 30.2%
uggesting a requirement for alternative strategies [9,10].
Almost  all neutralizing antibodies are directed against epitopes
n the DENV E protein and for this reason it is an obvious choice
or dengue subunit vaccines. CD8+ T cell epitopes in E are likely
o be less immunodominant than others in non-structural pro-
eins [25,28,29], but the renewed interest in cellular immunity
uggests these should not be ignored [25,28,36]. With this in mind
e wanted to evaluate CD8+ T cell immunity to the E protein
n our rMVA vectored dengue vaccines prior to testing antibody
esponses, but this required ﬁrst identifying CD8+ T cell epitopes
or DENV-3 E. Variants of D3E284–292 in other ﬂaviviruses have
reviously been shown to be CD8+ T cell epitopes with some cross-
eactivity across these viruses [30]. We  now show that this is also
n epitope of DENV-3 and responses to this peptide are also elicitedrMVA/Sg-E or rMVA/E and, 14 days later, serum samples were used in ELISA assays
to detect anti-E IgG antibodies. Data are represented as means and SEM from 2
experiments. *p ≤ 0.5; **p ≤ 0.01; ***p ≤ 0.001.
by rMVA E protein vaccines. D3E408–415 is entirely novel and it is
also signiﬁcantly more dominant than D3E284–292. Indeed in mice
immunized with rMVA vaccines, D3E408–415 was more immuno-
genic than the native MVA  A3270–277 epitope used for comparison,
which ranks second in the MVA  immunodominance hierarchy [37].
In contrast to C57BL/6 mice, none of the predicted H-2d-binding
peptides were found to be immunogenic in the context of our MVA
vaccine. This may  reﬂect the reliability of the predictive algorithms
for H-2d or the relatively poor immunogenicity of MVA  in BALB/c
mice [38].
Our  evaluation of rMVA/E vaccines demonstrates the value of
CD8+ T cell epitope information in vaccine development. Here we
show that a modiﬁcation of the DENV-3 E protein that strongly
improves humoral responses is also most likely superior for elici-
ting CD8+ T cells. The improvement in CD8+ T cell responses were
statistically signiﬁcant at acute times and in every memory exper-
iment the mean response was higher for groups immunized with
the ER-targeted E protein, even if generally not reaching signiﬁ-
cance. We  speculate that this may  also be the case for E proteins
expressed from vectors other than MVA.
Recent studies for several infectious diseases, including dengue,
suggest that the quality of CD8+ T cells, as demonstrated by their
ability to exert multiple functions, is important [39–45]. For exam-
ple, higher frequencies of CD8+ T cells expressing TNF-, IFN-,
and IL-2 in Thai children were associated with the development of
subclinical, rather than clinical secondary infection [46]. Another
study showed that higher and more polyfunctional responses in the
context of particular HLA alleles were associated with a decreased
susceptibility to severe disease [25]. Together these suggest that
a vigorous response by multifunctional CD8+ T cells is important
for protection against dengue. All rMVA vaccines evaluated here
elicited responses that included co-incident production of IFN-
and TNF- or production of IFN- and degranulation. In general the
ability of CD8+ T cells to produce cytokines after stimulation is in
the order: IFN-, TNF- and IL-2 [47]. In this context, the fraction of
IFN-+ CD8+ T cells also making TNF- was  approximately 80% for
all the vaccines, suggesting that all elicit a response of similar qual-
ity (not shown). Finally, all vaccines induced a response that was
able to kill targets displaying DENV-3 E-derived peptides in vivo.
In summary, these results suggest that the CD8+ T cell response
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licited by the rMVA vaccines tested here is polyfunctional and
mportantly this was not reduced by modifying the E protein to
mprove antibody responses.
In conclusion, we provide new tools for pre-clinical analysis
f cellular immune responses to DENV vaccines and use them to
emonstrate that the requisites for a good antigen can coincide
or humoral and CD8+ T cell immunity. This work adds to previous
tudies of an MVA  vector expressing DENV proteins tested in non-
uman primates [48]. Our results support further development of
VA  vectored dengue vaccines and show that targeting DENV E to
he ER improves cellular and humoral immune responses to this
mportant antigen.
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